DK2475645T3 - 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler - Google Patents

5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler

Info

Publication number
DK2475645T3
DK2475645T3 DK10749873.5T DK10749873T DK2475645T3 DK 2475645 T3 DK2475645 T3 DK 2475645T3 DK 10749873 T DK10749873 T DK 10749873T DK 2475645 T3 DK2475645 T3 DK 2475645T3
Authority
DK
Denmark
Prior art keywords
trifluor
dichlor
nicotinamide
ethoxy
cyclohexyl
Prior art date
Application number
DK10749873.5T
Other languages
Danish (da)
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2475645T3 publication Critical patent/DK2475645T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10749873.5T 2009-09-11 2010-09-08 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler DK2475645T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (1)

Publication Number Publication Date
DK2475645T3 true DK2475645T3 (da) 2013-07-22

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10749873.5T DK2475645T3 (da) 2009-09-11 2010-09-08 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler

Country Status (34)

Country Link
US (1) US8227491B2 (enExample)
EP (1) EP2475645B1 (enExample)
JP (1) JP5604520B2 (enExample)
KR (1) KR101382871B1 (enExample)
CN (1) CN102639506B (enExample)
AR (2) AR078352A1 (enExample)
AU (1) AU2010294277B2 (enExample)
BR (1) BR112012005511B8 (enExample)
CA (1) CA2771493C (enExample)
CL (1) CL2012000611A1 (enExample)
CO (1) CO6491033A2 (enExample)
CR (1) CR20120089A (enExample)
CY (1) CY1114377T1 (enExample)
DK (1) DK2475645T3 (enExample)
EC (1) ECSP12011723A (enExample)
ES (1) ES2423821T3 (enExample)
HR (1) HRP20130869T1 (enExample)
IL (1) IL217920A (enExample)
IN (1) IN2012DN00763A (enExample)
MA (1) MA33563B1 (enExample)
MX (1) MX2012002254A (enExample)
MY (1) MY161103A (enExample)
NZ (1) NZ597514A (enExample)
PE (1) PE20120863A1 (enExample)
PL (1) PL2475645T3 (enExample)
PT (1) PT2475645E (enExample)
RS (1) RS52987B (enExample)
RU (1) RU2541475C2 (enExample)
SG (1) SG179035A1 (enExample)
SI (1) SI2475645T1 (enExample)
TW (1) TWI412363B (enExample)
UA (1) UA107088C2 (enExample)
WO (1) WO2011029827A1 (enExample)
ZA (1) ZA201201599B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
ES2326280T3 (es) * 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
EP2074096B1 (en) 2006-10-04 2012-06-27 F. Hoffmann-La Roche AG 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
CA2771493A1 (en) 2011-03-17
CL2012000611A1 (es) 2012-09-07
AR114032A2 (es) 2020-07-15
ES2423821T3 (es) 2013-09-24
SG179035A1 (en) 2012-04-27
US8227491B2 (en) 2012-07-24
NZ597514A (en) 2013-10-25
KR101382871B1 (ko) 2014-04-08
TW201114427A (en) 2011-05-01
IL217920A (en) 2015-11-30
MY161103A (en) 2017-04-14
CO6491033A2 (es) 2012-07-31
PE20120863A1 (es) 2012-07-23
CN102639506B (zh) 2014-09-03
JP5604520B2 (ja) 2014-10-08
TWI412363B (zh) 2013-10-21
BR112012005511B8 (pt) 2021-05-25
EP2475645A1 (en) 2012-07-18
PT2475645E (pt) 2013-08-05
AU2010294277B2 (en) 2015-07-09
JP2013504534A (ja) 2013-02-07
RU2012113924A (ru) 2013-10-20
UA107088C2 (xx) 2014-11-25
AR078352A1 (es) 2011-11-02
RS52987B (sr) 2014-02-28
BR112012005511A2 (pt) 2016-04-19
HK1172021A1 (en) 2013-04-12
MX2012002254A (es) 2012-03-16
MA33563B1 (fr) 2012-09-01
RU2541475C2 (ru) 2015-02-20
IN2012DN00763A (enExample) 2015-06-26
CY1114377T1 (el) 2016-08-31
CA2771493C (en) 2017-08-29
AU2010294277A1 (en) 2012-02-09
PL2475645T3 (pl) 2013-12-31
BR112012005511B1 (pt) 2021-03-02
CN102639506A (zh) 2012-08-15
SI2475645T1 (sl) 2013-10-30
WO2011029827A1 (en) 2011-03-17
ZA201201599B (en) 2012-11-28
US20110065759A1 (en) 2011-03-17
HRP20130869T1 (hr) 2013-10-25
EP2475645B1 (en) 2013-07-03
CR20120089A (es) 2012-03-22
IL217920A0 (en) 2012-03-29
ECSP12011723A (es) 2012-04-30
KR20120048040A (ko) 2012-05-14

Similar Documents

Publication Publication Date Title
NO2022018I1 (no) Avacopan samt farmaceutisk acceptable salte deraf
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
BRPI1005995A2 (pt) implemento médico para manipular suturas, particularmente útil em cirurgia artroscópia
EP1962961A4 (en) DEMIKÖRPER: DIMERIZATION-ACTIVATED THERAPEUTIC AGENT
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
ATE509020T1 (de) 3-cyano-4-(4-tetrahydropyranphenyl)pyridin-2- onderivate
DK2234985T3 (da) 4-(4-cyano-2-thioaryl)-dihydropyrimidinoner og deres anvendelse
EP1901635A4 (en) SUPPORT FOR PATIENT
EP2432776A4 (en) METHYL-SULFANYL-PYRIMIDINE AS ANTI-INFLAMMATORY AGENTS, PAIN & ANTI-PILEPTICS
ATE541850T1 (de) Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
EP2170232A4 (en) LASER FOR REJUVENATING THE NETWORK SKIN
DK2445883T3 (da) Heterocykliske sulfonamider, anvendelser og farmaceutiske sammensætniger deraf
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
EP1908389A4 (en) MEDICAL CONTROLLER
BR112013012380A2 (pt) compostos 3-(aminoaril)-piridina
BRPI0815440A2 (pt) 5-substituidos 2- (alcoximetil) furanos
PL2306948T3 (pl) Urządzenie do chirurgii okulistycznej, zwłaszcza do refrakcyjnej chirurgii laserowej
BRPI1015416A2 (pt) "método para operar alto-forno"
BRPI0924140A2 (pt) pinça de microcirurgia, em particular pinça de capsulorrexe por microincisão
DK2122101T3 (da) Indretning med forhæng, som kan rulles op
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
EP2074770A4 (en) LINK AGGREGATION
DK2448927T3 (da) Hidtil ukendte (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amidderivater, fremstilling deraf og farmaceutisk anvendelse deraf som akt-phosphoryleringshæmmere
BRPI0810957A2 (pt) "emplasto medicamentoso compreendendo 5-metila-1-fenila-2-(1h) piridona".
ATE451356T1 (de) Substituierte arylsulfonamide als antivirale mittel